Yun-Seong Kang Selected Research

CT-P13

4/2015

Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yun-Seong Kang Research Topics

Disease

1	Pleural Effusion (Pleural Effusions) 01/2022
1	Hyperkalemia 01/2022
1	Pulmonary Tuberculosis 01/2022
1	Lung Diseases (Lung Disease) 01/2020
1	Respiratory Insufficiency (Respiratory Failure) 12/2018
1	Drug-Related Side Effects and Adverse Reactions 04/2015
1	Ulcerative Colitis 04/2015
1	Crohn Disease (Crohn's Disease) 04/2015
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 04/2015
1	Arthralgia (Joint Pain) 04/2015

Drug/Important Bio-Agent (IBA)

1	Linezolid (Zyvox)FDA Link 01/2022
1	delpazolidIBA 01/2022
1	ORALIT (ORS)IBA 01/2020
1	Oxygen (Dioxygen)IBA 12/2018
1	Infliximab (Remicade)FDA Link 04/2015
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2015
1	Biosimilar PharmaceuticalsIBA 04/2015
1	CT-P13IBA 04/2015

Therapy/Procedure

1	Therapeutics 12/2018
1	Cannula 12/2018